Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2021-06-02 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically identified as a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of recipients and the total number of shares. This type of filing, which concerns the issuance of stock options and capital-related changes, falls under the category of share issues or capital changes.
2021-06-02 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a '정정신고' (Amendment Report). It details changes to stock option grants, including the removal of a recipient and adjustments to total share counts. In the context of financial filings, reports regarding stock options, equity compensation, and capital structure changes that do not fit into specific categories like 'Director's Dealing' or 'Share Issue' are classified as Regulatory Filings (RNS) when they represent official corporate disclosures to financial authorities.
2021-06-02 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (directors/executives). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes in control.
2021-06-02 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange, specifically detailing a 'Decision on Paid-in Capital Increase' (유상증자결정) via third-party allocation. This is a formal regulatory filing regarding capital structure changes and share issuance. It is not a simple announcement (RPA) but the detailed regulatory report itself, fitting the 'Share Issue/Capital Change' category.
2021-05-31 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a formal 'Major Matters Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange regarding the issuance of convertible bonds (전환사채권 발행결정). It details the terms of the financing, including interest rates, conversion prices, put/call options, and the list of investors. This falls under the category of company fundraising and capital structure changes.
2021-05-31 Korean
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company Gencurix, covering the period from 2021.01.01 to 2021.03.31. It contains detailed financial information, company overview, capital structure, and management details, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.